As a key regulator of cytoskeletal dynamics, RHOA inhibition could affect both immune cells–where it modulates T–cell activation and migration–and cancer–associated fibroblasts (CAFs), which rely on RHOA for matrix remodelling and tumour invasion. Here, RHOA is linked to cancer.